Nucleus Genomics, IPO landscape, AI trend report

The hosts get together at 7am after Anika and Maya both managed to sleep through 6am alarms. This week the trio dives into Nucleus Genomics, the hot IPO market, and Mary Meeker’s AI trend report.

Nucelus Genoomics just launched a new product called Nucleus Embryo. Nucleus Embryo lets IVF parents compare embryos based not only on health markers, but also on traits like height, eye color, and even IQ. The hosts explain the science behind polygenic risk scores (PRS) versus traditional embryo screening for rare diseases. Finally they dive into the many controversies around genetic selection including the accuracy, risks of eugenics, potential for ableism, and the implications of a genetically engineered upper class that gets solified over multiple generations.

IPOs are so back. Circle, the company behind USDC, had a great IPO, jumping from $31 to $115 a share in a week. The hosts explain how Circle makes its money mostly from interest on the billions in reserves backing the stablecoin, thanks to high Fed rates. The discussion also touches on Circle’s failed SPAC attempt and why crypto might be going mainstream. They also cover Omada Health’s more modest IPO and discuss how digital health IPOs are slowly returning after a long dry spell post the pandemic era. Finally they go over potential IPOs rumored for the rest of the year.

The episode wraps with a breakdown of Mary Meeker’s hyped 2025 AI trend report. They dive into 340 pages of charts, graphs, and the word “unprecedented” (which is used 64 times!). The hosts discuss why ChatGPT adoption has been so much faster than Google. They also discuss how the commodization of AI is going to impact the business model of AI players.

00:00 Intro
03:04 Nucelus Genomics
27:14 IPO market including Circle and Omada Health
40:16 Mary Meeker’s AI trend report